Presentations & Publications

Science underlying Inspirna’s pipeline has been published in leading scientific journals and presented at renowned medical conferences.

Ompenaclid (RGX-202)

ESMO GI 2022 Poster

Phase 1b study of ompenaclid (RGX-202-01), a first-in-class oral inhibitor of the SLC6a8/CKB pathway, in combination with FOLFIRI and bevacizumab (BEV) in second-line advanced colorectal cancer (CRC)

ASCO 2022 Poster

Phase 1b study of ompenaclid (RGX-202-01), a first-in-class oral inhibitor of the SLC6a8/CKB pathway, in combination with FOLFIRI and bevacizumab (BEV) in second-line advanced colorectal cancer (CRC)

Science Advances - Oct 2021

Therapeutic targeting of SLC6A8 creatine transporter suppresses colon cancer progression and modulates human creatine levels.

ASCO 2020 Presentation

Phase 1 monotherapy dose-escalation of ompenaclid (RGX-202), a first-in-class oral inhibitor of the SLC6a8/CKB pathway, in patients with advanced gastrointestinal (GI) solid tumors

AACR 2018 Presentation

Ompenaclid (RGX-202), a first-in-class small-molecule inhibitor of the creatine transporter SLC6a8, is a robust suppressor of cancer growth and metastatic progression

Cell - Jan 2015

Extracellular Metabolic Energetics Can Promote Cancer Progression (Cell160, 393–406, January 29, 2015)

Abequolixron (RGX-104)

AACR 2020 Poster

Correlative analysis of pharmacokinetics and pharmacodynamics of RGX-104, a first-in-class Liver-X-Receptor (LXR) agonist, and clinical outcomes in patients with advanced solid tumors

AACR 2020 Presentation

RGX-104, a first-in-class immunotherapy targeting the Liver-X Receptor (LXR); Initial results from the Phase 1b RGX-104 plus Docetaxel combination dose escalation cohorts

ASCO 2018 Poster

Pharmacodynamic and clinical activity of RGX-104, a first-in-class immunotherapy targeting the liver-X nuclear hormone receptor (LXR), in patients with refractory malignancies

Cell - Feb 2018

LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer (Cell172, 1–16, February 8, 2018)

Cell - Feb 2014

Broad-Spectrum Therapeutic Suppression of Metastatic Melanoma through Nuclear Hormone Receptor Activation (Cell156, 1–16, February 27, 2014)

Cell - Nov 2012

Convergent Multi-miRNA Targeting of ApoE Drives LRP1/LRP8-Dependent Melanoma Metastasis and Angiogenesis (Cell151, 1068–1082, November 21, 2012)

RGX-019

AACR 2020 Poster

In vivo efficacy and safety of RGX-019, a MerTK targeting monoclonal antibody

AACR 2019 Presentation

Characterization of the anti-cancer and immunologic activity of RGX-019, a novel pre-clinical stage humanized monoclonal antibody targeting the MERTK receptor

Discovery Platform

Nature Cell Biology - Jun 2013

Control of Metastatic Progression by microRNA Regulatory Networks (Nat Cell Biol. 2013 Jun; 15(6): 546–554)

Nature - Oct 2012

A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells (Nature 481, 190–194 (2012)

Nature - Jan 2008

Endogenous human microRNAs that suppress breast cancer metastasis (Nature volume 451, pages147–152(2008))

Presentations & Publications

Ompenaclid (RGX-202)

ESMO GI 2022 Poster

ASCO 2022 Poster

Science Advances - Oct 2021

ASCO 2020 Presentation

AACR 2018 Presentation

Cell - Jan 2015

Abequolixron (RGX-104)

AACR 2020 Poster

AACR 2020 Presentation

ASCO 2018 Poster

Cell - Feb 2018

Cell - Feb 2014

Cell - Nov 2012

RGX-019

AACR 2020 Poster

AACR 2019 Presentation

Discovery Platform

Nature Cell Biology - Jun 2013

Nature - Oct 2012

Nature - Jan 2008

Twitter Feed

Inspirna

Newsletter